Published July 2, 2026
May 31, 2026. The American Society of Clinical Oncology’s annual meeting in Chicago. A much-anticipated presentation is made. For a moment … stunned silence. Then the room erupts. An auditorium packed with an estimated 18,000 oncologists, researchers, and advocates rises to its feet and cheers for over a minute. Some with tears in their eyes. A lead researcher from Dana-Farber Cancer Institute had just clicked to a slide showing a new drug had cut the risk of death by 60 percent for patients with one of the most feared diagnoses in medicine: metastatic pancreatic cancer. Physicians who had spent sixteen, twenty, even thirty years watching this disease defeat every new idea thrown at it were on their feet. Something big had finally happened.
What Did the Presentation Reveal?
For over forty years, scientists have known that more than 90 percent of pancreatic cancers are driven by a mutated gene called KRAS. It produces a protein that acts like a switch stuck permanently in the “on” position, signaling cells to grow and divide without restraint. The trouble is that KRAS is a smooth protein — round, featureless, with almost nothing to grab onto. Most drugs work by finding a pocket or groove on a protein’s surface, the way a key fits a lock. KRAS was a locked door and there was no keyhole. It was a mountain with no hand holds. Imagine trying to climb a mountain made of polished marble. For decades, it was simply labeled “undruggable,” and researchers moved on to easier targets.
Revolution Medicines took a different approach. Rather than searching for a pocket that did not exist, their researchers designed what is called a molecular glue. They discovered that daraxonrasib first latches onto a completely separate protein already present inside the cell — a chaperone protein called cyclophilin A. The daraxonrasib-cyclophilin A pair then slides into a subtle interface that only opens up when KRAS is actively “on.” Like warriors sneaking in via the famous Trojan horse — daraxonrasib is carried inside by cyclophilin A as the wooden horse. Once inside, it can stop KRAS. The trio clamps together into a tight complex, KRAS is blocked from pumping out its growth signals, the cells soon die, and the tumor shrinks.
So why doesn’t daraxonrasib poison the patients who take it? Because in healthy cells, KRAS spends most of its time in the “off” state. That selectivity is a large part of why the drug works broadly and with a more tolerable side effect profile than traditional chemotherapy.
The results, published simultaneously in the New England Journal of Medicine, were striking. In the trial of 500 patients whose cancer had already progressed on prior treatment, those given daraxonrasib lived a median of 13.2 months compared to 6.7 months on standard chemotherapy — a 60 percent reduction in risk of death. Patients stayed on the drug far longer, with far fewer side effects forcing them to stop. Many reported better quality of life and significantly less pain. The FDA has already granted it Breakthrough Therapy status and opened an expanded access program, meaning some patients can receive it now, before formal approval, if their oncologist applies on their behalf.
“A Miracle Drug”
Already, there are early adopters even before FDA approval. Among them is former US Senator Ben Sasse, who enrolled in a clinical trial for this drug, daraxonrasib, after being told last December he had three to four months to live. His tumors had spread to his lungs, liver, and vascular system. On CBS’s 60 Minutes, he credited his turnaround to “providence, prayer, and a miracle drug,” telling anchor Scott Pelley: “I have much, much less pain than I had four months ago when I was diagnosed, and I have a massive 76% reduction in tumor volume over the last four months.” His story has put a human face on a disease that quietly takes more than 50,000 American lives each year.
What About Other Cancers?
This is where things get truly exciting.
KRAS mutations drive not just pancreatic cancer but also a significant proportion of colorectal cancers, non-small cell lung cancers, bile duct cancers, and others. Revolution Medicines is already testing daraxonrasib in these tumor types. But the most remarkable finding may come from a separate laboratory. Earlier this year, world-renowned cancer geneticist Dr. Mariano Barbacid at Spain’s National Cancer Research Centre published a study in the Proceedings of the National Academy of Sciences testing a triple-drug combination: daraxonrasib to block KRAS itself, afatinib to block the upstream EGFR receptor on the cell surface that feeds into the KRAS pathway, and SD36, an experimental compound that degrades a separate survival protein called STAT3 that tumors activate as an escape route when KRAS alone is blocked. Three simultaneous locks on three different doors.
The results in mouse models were unlike anything seen before in this disease. Tumors disappeared completely — and did not return for over 200 days after treatment ended (200 days in a mouse is like years and years in a human). The therapy was well tolerated with minimal toxicity. Human trials have not yet begun, but the biology is sound, and the implications are profound. If cancer cannot grow through pathway one, or reroute through pathway two, or survive via pathway three — it has nowhere left to go.
The Hidden Door
For now, daraxonrasib alone is not a cure. But for a disease that has resisted nearly every advance in modern oncology for half a century, nearly doubling survival with a once-daily pill is nothing short of remarkable. It is a reminder that even what seems permanently locked — smooth, featureless, with nothing to grab onto — can yield when someone is patient and clever enough to find the hidden door.
I think this is a good analogy for life. When it sometimes seems like there is no way, a way can open by God’s grace and by persistently seeking. KRAS was smooth — no openings —a locked door. There was no way to open it….but then there was. And now it’s open. Revelation 3:8 says “See, I have placed before you an open door that no one can shut.” I think when Senator Sasse says the way opened by “providence, prayer, and a miracle drug” — he was onto something.
Blessings, Dr. Jeff Ponke, MD Forest Direct Primary Care
Leave a comment